On these bases, BIRC3 disruption may contribute to expand the panel of biomarkers for the early identification of chemorefractory cases.15 In addition, BIRC3 abnormalities provide a molecular rationale for targeting NF-κB in poor risk and chemorefractory CLL. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.